Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Translesion DNA Polymerases

Translesion DNA Polymerases

Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood pressure variability plays a critical role in determining the prognosis of acute ischemic stroke combined with hypertension.

Frontiers in neurology·2026

Same author

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

The oncologist·2026

Same author

A Bioinspired Exosomal Nanoplatform for Coordinated Sorafenib and MicroRNA Delivery to Sensitize Ferroptosis and Induce Immunoactivation in Triple-Negative Breast Cancer.

ACS nano·2026

Same author

Single-Atom Barium-Mediated Hydrogen-Bonding Interaction via Mortise-and-Tenon Interlock for Rechargeable Biomass Electrooxidation in Pure Water.

Angewandte Chemie (International ed. in English)·2026

Same author

Application of transjugular liver biopsy in pediatric living donor liver transplantation.

BMC gastroenterology·2026

Same author

Analysis of ultrasound features and clinical manifestations of struma ovarii.

Frontiers in oncology·2026

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Published on: July 14, 2023

Links between DNA polymerase beta expression and sensitivity to bleomycin.

Shukun Liu¹, Yanhao Lai, Wei Zhao

¹Department of Environmental Health, Sichuan University, West China School of Public Health, Chengdu, PR China.

|January 22, 2011

Summary

DNA polymerase beta (pol β) deficiency enhances bleomycin (BLM) anti-tumor drug sensitivity by impairing DNA repair. Lack of pol β increases oxidative DNA damage and mutations, making cancer cells more vulnerable to BLM treatment.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Dual Immunofluorescence of γH2AX and 53BP1 in Human Peripheral Lymphocytes

Published on: July 14, 2023

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Area of Science:

Molecular Biology
Cancer Research
Genetics

Background:

Bleomycin (BLM) is an anti-tumor antibiotic causing cell death via oxidative DNA damage.
Cellular resistance to BLM limits its clinical efficacy.
Base excision repair (BER) pathway, involving DNA polymerase beta (pol β), repairs oxidative DNA damage and influences resistance to anticancer drugs.

Purpose of the Study:

To investigate the role of DNA polymerase beta (pol β) in bleomycin (BLM)-induced DNA damage and cellular sensitivity.
To determine if inhibiting pol β can enhance BLM's anti-tumor effects.

Main Methods:

Comparison of BLM sensitivity in mouse embryo fibroblasts (MEFs) with wild-type and pol β-deficient genotypes.
Assessment of reactive oxygen species (ROS) levels, DNA single-strand breaks, and chromosomal aberrations.
Measurement of hprt gene mutation frequency.

Main Results:

Pol β-deficient MEFs exhibited significantly lower cell viability upon BLM treatment compared to wild-type cells.
Pol β deficiency led to increased ROS levels, DNA single-strand breaks, and chromosomal damage.
Absence of pol β resulted in a higher frequency of hprt gene mutations.

Conclusions:

The BER pathway, particularly pol β, plays a critical role in repairing BLM-induced oxidative DNA damage.
Pol β deficiency impairs DNA repair, leading to enhanced oxidative DNA damage, chromosomal instability, and gene mutations.
The absence of pol β contributes to hypersensitivity to bleomycin, suggesting pol β as a potential therapeutic target to overcome BLM resistance.